Business
Update on Acquisition of Lyramid Limited
Update on Acquisition of Lyramid Limited.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 2223S\n Roquefort Investments PLC\n 12 November 2021\n \n \n \n \n 12 November 2021\n \n \n \n \n \n \n \n \n Roquefort Investments plc\n \n \n (\"Roquefort Investments\" or the \"Company\")\n \n \n \n \n \n Update on Acquisition of Lyramid Limited\n \n \n \n \n \n Roquefort Investments (LSE:ROQ), the London listed \n investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector\n , is pleased to announce that it has commenced marketing to potential investors to fund the acquisition and pre-clinical drug development programme of Lyramid Limited, details of which were announced on 29 September 2021. A copy of the presentation is available on the Company's website at \n \n \n https://www.roquefortinvest.com/presentations\n \n \n \n \n \n \n \n The Company looks forward to providing further updates in relation to the acquisition of Lyramid Limited as and when appropriate.\n \n \n \n \n \n The Company's shares remain suspended from trading \n on the Main Market of the London Stock Exchange \n pending the publication of a Prospectus setting out full details of the potential transaction.\n \n \n \n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n \n Roquefort Investments plc\n \n \n \n \n \n \n Stephen West (Chairman)\n \n \n \n \n +44 (0)20 3290 9339\n \n \n \n \n \n \n Optiva Securities Limited (Joint Broker)\n \n \n \n \n \n \n \n \n \n \n \n \n \n Christian Dennis\n \n \n \n \n +44 (0)20 3411 1881\n \n \n \n \n \n \n \n \n For further information, please \n visit \n \n \n www.roquefortinvest.com\n \n \n and @roquefortinvest on Twitter.\n \n \n \n \n \n LEI: 254900P4SISIWOR9RH34\n \n \n \n This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as ...